View More Recent Stories

Feb 16, 2018 08:00AM Top Line Results From Aironite Phase 2 Clinical Trial for the Treatment of HFpEF to Be Presented at American College of Cardiology 67th Annual Scientific Sessions & Expo on March 11th
Feb 12, 2018 08:03AM Savara (SVRA) Reports IND Approval for Expansion of Molgradex Phase 3 Study Into U.S.
Feb 12, 2018 08:00AM Savara Announces IND Approval for Expansion of Molgradex Phase 3 Study Into U.S.
Feb 6, 2018 08:00AM Savara Reports Publication of Case Reports of Inhaled Granulocyte-Macrophage Colony Stimulating Factor for the Treatment of Nontuberculous Mycobacteria
Feb 5, 2018 08:00AM Savara to Present at the 20th Annual BIO CEO & Investor Conference on February 12th
Jan 4, 2018 08:00AM Savara Announces Appointment of Peter Ginsberg as Vice President of Business Development
Dec 21, 2017 08:00PM Savara Submits Investigational New Drug Application to FDA for Expansion of Molgradex Impala Study Into U.S.
Dec 18, 2017 08:00AM Savara Added to Nasdaq Biotechnology Index
Nov 29, 2017 08:10AM Savara (SVRA) Secures $5M Award from Cystic Fibrosis Foundation Therapeutics Inc. for Development of AeroVanc
Nov 29, 2017 08:00AM Savara Receives $5 Million Award From Cystic Fibrosis Foundation Therapeutics, Inc. for the Development of AeroVanc
Nov 13, 2017 08:00AM Savara to Present at the Jefferies 2017 London Healthcare Conference on November 16th
Nov 8, 2017 04:01PM Savara Reports Third Quarter 2017 Financial Results and Provides Business Update
Nov 1, 2017 08:00AM Savara to Host Third Quarter 2017 Financial Results and Business Update Conference Call on Wednesday November 8, 2017
Oct 24, 2017 04:01PM Savara Announces Expansion of Molgradex Development to Include Treatment of Nontuberculous Mycobacterial (NTM) Lung Infection
Oct 19, 2017 08:00AM Savara Announces Uplisting to the Nasdaq Global Select Market(R)
Oct 18, 2017 08:05AM Savara (SVRA) Completes Enrollment in Phase 2 Clinical Trial of Aironite for Treatment of HFpEF
Oct 18, 2017 08:00AM Savara Reports Completion of Enrollment in Phase 2 Clinical Trial of Aironite for the Treatment of HFpEF
Sep 26, 2017 08:02AM Savara (SVRA) Begins Pivotal Phase III AVAIL Study of AeroVanc
Sep 26, 2017 08:00AM Savara Announces Start of Pivotal Phase III AVAIL Study of AeroVanc
Sep 21, 2017 08:00AM Savara to Present at the Cantor Fitzgerald 2017 Global Healthcare Conference on September 27th
Sep 5, 2017 08:00AM Savara to Present at the Rodman & Renshaw 19th Annual Global Investment Conference on September 11th
Aug 9, 2017 08:00AM Savara Reports Second Quarter 2017 Financial Results and Provides Business Update
Jul 11, 2017 08:05AM Savara (SVRA) Announces Presentation of Positive Interim Results of Aironite Phase 2 Study
Jul 11, 2017 08:00AM Positive Interim Results Of Aironite Phase 2 Study Presented At 4th Annual Drug Discovery And Development Symposium For Pulmonary Hypertension
Jun 20, 2017 08:00AM Savara Set To Join Russell Microcap® Index
Jun 5, 2017 08:00AM Savara To Present At The Jefferies 2017 Global Healthcare Conference On June 9th
May 10, 2017 09:18AM Savara (SVRA) Announces Expedited Molgradex Development Strategy Following Guidance from FDA
May 10, 2017 08:00AM Savara Announces Expedited U.S. Molgradex Development Strategy
May 8, 2017 08:12AM Savara (SVRA) Receives Composition of Matter Patent Covering AeroVanc
May 8, 2017 08:00AM Savara Announces Issuance Of U.S. Composition Of Matter Patent Covering AeroVanc
May 1, 2017 08:00AM Savara Secures $15 Million Loan And Security Agreement With Silicon Valley Bank
Apr 28, 2017 02:01PM Savara Announces Closing Of Merger With Mast Therapeutics
Apr 27, 2017 04:15PM Savara Announces Closing Of Merger With Mast Therapeutics
View More Recent Stories